Novotech Showcased in Global Biotech Series for Innovation in Hepatitis B Research
Sydney, Australia:
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by the Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610224929/en/
Novotech, a global (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by BIO and produced by BBC StoryWorks Commercial Productions.
The Next Frontier explores how biotechnology is addressing some of the world's most urgent health and sustainability challenges. As part of the series, Novotech highlights its partnership with Tune Therapeutics in advancing a functional cure for Hepatitis B, a chronic disease impacting nearly 300 million people globally. As the global leader in Hepatitis clinical trials, Novotech brings deep therapeutic expertise and global execution capabilities to accelerate development and delivery for sponsors.
Filmed in New Zealand with world-leading hepatologist Professor Edward Gane, where an estimated 100,000 people are living with Hepatitis B, the feature highlights Novotech's partnership model for supporting biotech and small to mid-size pharma sponsors. It demonstrates how Novotech accelerates clinical development through access to expert investigators, targeted patient populations, and efficient trial infrastructure across Asia-Pacific, Europe, and North America, while showcasing its global capabilities in infectious disease research and trial delivery.
'Our inclusion in this series reflects Novotech's commitment to supporting innovators with smarter, faster, and more regionally tailored clinical solutions,' said Tom Hickey, Director of Therapeutic Strategy. 'Hepatitis B remains a significant global health challenge, and our teams are proud to have such a long history contributing to meaningful progress in this area.'
The series will officially launch at the BIO International Convention in Boston on June 16, 2025, and is now available globally via digital platforms at BBC.com .
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide.
Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610224929/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
GeoVax to Participate in BIO International Convention 2025
ATLANTA, GA - June 12, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced that company representatives will attend the 2025 BIO International Convention being held June 16-19, 2025 at the Boston Convention and Exhibition Center in Boston, Massachusetts. The BIO International Convention is the world's largest gathering of the biotechnology industry, attracting thousands of biotechnology and pharmaceutical executives from around the globe. The event provides an ideal venue for companies to engage with potential partners, investors, and policymakers. During the convention, GeoVax will participate in business development and partnering meetings to discuss its expanding pipeline of infectious disease and cancer immunotherapies, including GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting Mpox and smallpox; GEO-CM04S1, a multi-antigen COVID-19 vaccine candidate; and Gedeptin(R), a gene-directed enzyme prodrug therapy for the treatment of solid tumors. GeoVax's participation at BIO 2025 supports its broader business development strategy, including ongoing efforts to establish strategic partnerships, expand manufacturing capabilities, and align with public and private sector priorities in pandemic preparedness, oncology, and biodefense. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Company Contact:info@ Investor Relationsgeovax@ Contact: Media Contact:Jessica Starmanmedia@ View the original release on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 hours ago
- Yahoo
DPH chief: Mass. prepared to maintain vaccine access
BOSTON (SHNS) – The state public health chief called the firing of all 17 members of a federal vaccine advisory panel 'troubling' on Wednesday, while acknowledging that Massachusetts officials have been bracing for such a scenario. On Monday, U.S. Health and Human Services Secretary Robert Kennedy Jr. dismissed all members of the CDC's Advisory Committee for Immunization Practices, or ACIP. President Joe Biden's administration had appointed all 17 members, including 13 in 2024, and 'these appointments would have prevented the current administration from choosing a majority of the committee until 2028,' Kennedy's office said. 'In dismissing the members, the secretary stated his intention to repopulate the committee and to hold the scheduled ACIP meeting June 25 to June 27,' Public Health Commissioner Robbie Goldstein said. 'This news is troubling. It amends a science-based process that has informed vaccine recommendations and promoted vaccine access for decades. The future of federal vaccine policy is unclear.' In a statement Monday, Kennedy said the move was 'necessary to reestablish public confidence in vaccine science.' New members were not announced but Kennedy's office said they will 'ensure that government scientific activities are informed by the most credible, reliable, and impartial scientific evidence available.' At a virtual state Public Health Council meeting Wednesday, Goldstein said it's unclear if new ACIP members 'will continue to use evidence and science to guide our vaccine recommendations and vaccine policy.' 'We've been been preparing for a number of scenarios, including this one, and we are well positioned to respond and maintain access to vaccines across the state,' Goldstein said. 'Starting in November, we've been analyzing the legal and regulatory landscape, identifying resources that could be used to guide vaccine recommendations, strengthening our data systems to understand vaccine effectiveness, and building a coalition of like-minded, evidence-based public health organizations in this state and others.' The Massachusetts Vaccine Purchasing Advisory Council, which helps distributes vaccines recommended by the ACIP, is slated to meet Thursday in Waltham. At a public hearing on Friday, Massachusetts parents and medical providers urged state lawmakers to scrap religious exemptions for school immunization requirements. The plea came amidst measles outbreaks in the U.S. Meanwhile, vaccine opponents lamented potential state infringements on their faith and personal beliefs. Students from preschool to college are required to receive a bevy of vaccines, including for polio, Hepatitis B, and measles, mumps and rubella, according to the state Department of Public Health. State law allows students to seek medical and religious exemptions, and refiled bills from Rep. Andy Vargas and Sen. Edward Kennedy (H 2544 / S 1557) would eliminate the religious carveout for immunizations required in public, private and charter K-12 schools. Under the proposals, schools must submit data annually to DPH about how many students are vaccinated and how many received a medical exemption — with that information then made publicly available. 'Three of our Northeast neighbors — Connecticut, Maine and New York — have eliminated their non-medical vaccine exemptions in recent years,' Katie Blair, executive director of Massachusetts Families for Vaccines, told the Joint Committee on Public Health. 'They have seen subsequent improvements in immunization rates, increasing the herd immunity protection that their most medically vulnerable residents depend upon. It's time for Massachusetts to do the same.' The committee reported the legislation out favorably at the end of last session on Dec. 16. Democrats in the Health Care Financing Committee did not advance the proposal. The majority of vaccine exemptions are for religious reasons in Massachusetts, according to DPH. Some western and southeastern parts of the state, especially on the Cape and Islands, have higher rates of vaccine exemptions, and those areas 'may be more susceptible to disease outbreaks because these students are not fully protected,' DPH says. Kyle Abrahamson, a biomedical engineer, said he opposed the bills because they encroach on his 'free exercise of religion' and constitute 'tyrannical overreach' from state government. Abrahamson argued that removing the religious exemption would force him to choose between his faith and his child's education. He also spoke against Sen. Becca Rausch's so-called Community Immunity Act (S 1618) that would preserve religious vaccine exemptions but strengthen the exemption process and improve data reporting. 'Parents — not the state, nor any medical professional or anybody else — but parents are the paramount advocates for their own children,' Abrahamson said. 'If H 2554, S 1557 and S 1618 move forward, the state is taking away parents' faith and forcing parents to put their faith in them.' Julie Booras, co-founder of Health Rights Massachusetts, said she 'strongly' opposes all school-related vaccine bills before the committee. She testified in support of a Rep. John Gaskey bill (H 2431) that would block the state from requiring COVID-19 shots, mRNA vaccines or gene-altering procedures to enroll in K-12 schools, colleges or universities, as well as to enter private businesses or seek employment. 'This bill is critical to ensure the injustices of the COVID era can never happen again,' Booras said. 'Despite all of the information now available about the physical, emotional and financial harms caused by the COVID countermeasures, nothing has changed. No meaningful action has been taken to rein in the sweeping powers granted to the governor and public health agencies by the Massachusetts Legislature.' Vaccine supporters had emphasized new urgency over removing religious exemptions as they invoked the worsening measles outbreak in Texas and other hotspots. Texas has logged 744 measles cases since January, causing 96 people to be hospitalized and two deaths among school-aged children, according to the Texas Department of State Health Services. There were 1,168 confirmed measles cases and three confirmed deaths across the U.S. as of June 5, according to the latest data from the Centers for Disease Control and Prevention. Massachusetts has not recorded any cases. 'Measles is an awful disease with dangerous complications and side effects,' Dr. Richard Moriarty, a retired pediatric infectious disease specialist, said. 'With cuts in health care funding, how are we going to pay if there are outbreaks? Outbreaks are very expensive.' Moriarty did not specify the funding cuts, but the Trump administration has moved to slash billions of dollars in public health grants and congressional Republicans are advancing proposals to drastically cut Medicaid dollars to states. 'Measles is so infectious, we need 95% of a population immunized to prevent an outbreak,' Moriarty continued. 'We thought our schools were good in Massachusetts, but if you take a deep dive into them, 119 kindergartens have MMR rates less than 90%, 31 schools are below 80% in Massachusetts, 19% of our schools didn't even bother to report their immunization rates this year, and 24% report their rates only on rolling three-year averages.' Supporters emphasized that vaccine skepticism and misinformation is more common across the country, and the landscape is also marked by shifting federal vaccine recommendations and immunization schedules. 'My colleagues are spending so much time just re-educating parents who have trusted the medical system for years and now have been instilled with this fear, which is completely based on misinformation,' said Dr. Christina Hermos, division chief of infectious disease at UMass Memorial Children's Medical Center. 'The frontline pediatricians are burning out having these conversations. We're already having a crisis of people going into primary care across this nation.' Kennedy last month announced the CDC is no longer recommending COVID vaccines for healthy children and pregnant individuals. Goldstein on Wednesday said that COVID vaccines remain available. He stressed that vaccinating pregnant women can protect newborn babies who cannot get immunized yet. 'I want to be clear: We know that COVID vaccination prevents severe illness, hospitalization and death in those at risk, which includes children and pregnant people,' Goldstein said. 'DPH will continue to lift up the data and the evidence that are available to inform our recommendations. And we'll work with insurers, health care providers and others across the state to maintain access to evidence-based safe vaccines.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
21 hours ago
- Yahoo
New Mexico Delegation to Promote the State's Bioscience Industry at BIO International Convention in Boston
Delegates from public, private, and higher education entities will participate in the New Mexico Pavilion to create new connections and drive interest in the state's bioscience industry Albuquerque, NM, June 11, 2025 (GLOBE NEWSWIRE) -- A delegation of government, economic development, association and industry leaders and businesses will represent the New Mexico bioscience industry at the BIO International Convention in Boston June 16-19. The Albuquerque Regional Economic Alliance (AREA) will promote the New Mexico bioscience industry, learn about the latest bioscience trends, and connect with companies interested in relocating or expanding their business in greater Albuquerque. 'The greater Albuquerque region has a growing number of bioscience assets and workforce clusters that make it a prime location for medical technology companies,' said AREA President & CEO Danielle Casey. 'This conference gives us an opportunity to highlight assets driving that growth, to understand how to best support our local firms and to see how trends and technology are shaping site location and expansion decisions.' Representatives from AREA will exhibit at the conference with partners from Presbyterian Health, UNM Health Sciences, the New Mexico Bioscience Authority, Sandoval Economic Alliance, the New Mexico Economic Development Department, Tricore, Los Alamos National Labs. The City of Albuquerque, Bernalillo County and Sandoval County are also serving as sponsors of this effort. Each partner will highlight different aspects of the bioscience industry, which is broadly defined as any science that deals with the biological aspects of living organisms, by showcasing their respective organizations. 'Bernalillo County is ready and eager to partner with biotechnology businesses looking to expand in central New Mexico,' said Marcos Gonzales, Executive Development Officer for Bernalillo County. 'The I-40 TradePort Corridor is a key asset for companies seeking to integrate national or regional logistics and distribution capabilities into their growth strategies. If your expansion plans include logistics automation or multi-modal connectivity, we're here to find the right solution together.' 'The University of New Mexico Health Sciences Office of Research is honored to participate in the 2025 BIO International Convention,' said Dr. Hengameh Raissy, Vice President of Research at UNM Health Sciences. 'As part of the New Mexico booth, our team is eager to showcase groundbreaking research, build strategic partnerships, and explore new opportunities for collaboration that drive advancements in health and biomedical sciences. We are excited to engage with global leaders in biotechnology and life sciences, and to highlight the impactful work taking place at UNM Health Sciences and throughout New Mexico.' A featured and exciting showcase will occur on Tuesday, June 17 during the main exhibit hall reception, courtesy of Visit Albuquerque, where booth visitors will experience the thrill of a hot air balloon ride from the safety of the ground through virtual reality. The region has seen consistent growth within the industry, thanks to high concentrations of technical occupations, key regional assets like national laboratories and top-tier research universities, and a statewide talent pipeline of STEM-based graduates that has seen steady growth over the past five years. Overall, the state of New Mexico has seen a 26% job growth increase in the past five years in the bioscience cluster and 3,970 Statewide STEM Graduates. 'Albuquerque offers the innovation ecosystem, workforce, and infrastructure needed to help bioscience companies thrive and scale,' said Economic Development Director Max Gruner. 'We're committed to meeting businesses where they are and building new partnerships.' The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with over 20,000 industry leaders from across the globe. It is regarded as one of the most significant gatherings in the industry, providing a platform for New Mexico to connect and make strategic connections with investors, businesses interested in their research or products, and industry leaders from the pharmaceutical, med tech, life science, health care, government, and academic institutions. The Exhibition showcases over 500 exhibitors offering cutting-edge solutions in product development, contract research, contract manufacturing, and beyond, providing the New Mexico bioindustry an opportunity to build new partnerships and increase visibility and brand awareness of New Mexico as a leading location to do business. To view the New Mexico delegation's schedule of booth events and representatives, as well as reports and data on the bioscience industry in New Mexico, visit For more information about the conference, visit: About AREAThe Albuquerque Regional Economic Alliance is a 501(c)(3) nonprofit organization whose mission is to lead and execute strategies designed to grow and diversify the economic base of the greater Albuquerque region, creating a prosperous, diverse and inclusive economy and elevating the standard of living for all. AREA provides confidential assistance to businesses considering the area for expansion and new investment. Since its creation in 1960, AREA has recruited more than 250 companies and more than 35,000 jobs to the Albuquerque metro area. AREA also provides retention and expansion assistance to existing industry. For more information, visit CONTACT: Danielle Casey Albuquerque Regional Economic Alliance 505-705-3785 dcasey@
